Noorlander C W, De Graan P N E, Middeldorp J, Van Beers J J B C, Visser G H A
Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands.
J Comp Neurol. 2006 Dec 20;499(6):924-32. doi: 10.1002/cne.21162.
Women at risk for preterm delivery are treated with synthetic glucocorticoids (GCs) to enhance fetal lung maturation. GCs can bind to two intracellular receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which function as transcription factors. Both are highly expressed in the hippocampus. Several studies have focused on adverse side effects of antenatal GC treatment. However, relatively little is known about the ontogeny of GR and MR, especially in human. Therefore, we studied the ontogeny of both receptors in the human and mouse hippocampus and investigated the effects of antenatal dexamethasone (dex) treatment, a synthetic glucocorticoid, on MR and GR mRNA levels during hippocampal development. The results demonstrate that MR mRNA was first expressed in mouse hippocampus at embryonic day (E)15.5, at the timepoint when dex was administered. In contrast, GR mRNA expression was first observed after birth at postnatal day (P)5. However, in the human hippocampus both receptors are expressed at 24 weeks of gestation, when antenatal GCs are administered in clinical practice. Quantitative in situ hybridization demonstrated that MR mRNA levels were reduced only shortly after dex treatment at E16, but were unaffected from E18 onwards. These findings indicate that a single antenatal dex administration at E15.5 transiently affects MR mRNA levels in the mouse hippocampus. No effect of antenatal dex treatment was found on the human hippocampus at the third trimester of pregnancy. These data on the prenatal ontogeny of both corticosteroid receptors in the human hippocampus is important for understanding the significance of fetal glucocorticoid or stress exposure and its potential effects on health and disease.
有早产风险的孕妇会接受合成糖皮质激素(GCs)治疗,以促进胎儿肺成熟。GCs可与两种细胞内受体结合,即糖皮质激素受体(GR)和盐皮质激素受体(MR),它们作为转录因子发挥作用。二者在海马体中均高度表达。多项研究聚焦于产前GC治疗的不良副作用。然而,对于GR和MR的个体发生,尤其是在人类中的情况,人们了解得相对较少。因此,我们研究了人类和小鼠海马体中这两种受体的个体发生,并调查了产前地塞米松(dex)治疗(一种合成糖皮质激素)对海马体发育过程中MR和GR mRNA水平的影响。结果表明,MR mRNA在小鼠海马体中于胚胎期第15.5天(E15.5)首次表达,此时正是给予dex的时间点。相比之下,GR mRNA表达在出生后第5天(P5)才首次被观察到。然而,在人类海马体中,这两种受体在妊娠24周时均有表达,而这正是临床实践中给予产前GCs的时间。定量原位杂交显示,仅在E16给予dex治疗后不久MR mRNA水平降低,但从E18起未受影响。这些发现表明,在E15.5单次产前给予dex会短暂影响小鼠海马体中的MR mRNA水平。在妊娠晚期,未发现产前dex治疗对人类海马体有影响。这些关于人类海马体中两种皮质类固醇受体产前个体发生的数据,对于理解胎儿糖皮质激素或应激暴露的意义及其对健康和疾病的潜在影响至关重要。